

Solid-Phase Synthesis of Dihydrovirginiamycin S₁, a Streptogramin B Antibiotic

Alex Shaginian,^[a] Marissa C. Rosen,^[a] Brock F. Binkowski,^[b] and Peter J. Belshaw^{*,[a, b]}

Abstract: We describe the first solid-phase synthesis of dihydrovirginiamycin S₁, a member of the streptogramin B family of antibiotics, which are nonribosomal-peptide natural products produced by *Streptomyces*. These compounds, along with the synergistic group A components, are “last line of defense” antimicrobial agents for the treatment of life-threatening infections such as vancomycin-resistant enterococci. The synthesis features an on-

resin cyclization and is designed to allow production of streptogramin B analogues with diversification at positions 1', 1, 2, 3, 4, and 6. Several synthetic challenges known to hinder the synthesis of this class of compounds were solved, including sensitivity to

Keywords: antibiotics • cyclic peptides • depsipeptides • solid-phase synthesis • virginiamycins

acids and bases, and epimerization and rearrangements, through the judicious choice of deprotection conditions, coupling conditions, and synthetic strategy. This work should enable a better understanding of structure–activity relationships in the streptogramin B compounds, possible identification of analogues that bypass known resistance mechanisms, and perhaps the identification of analogues with novel biological activities.

Introduction

The streptogramin (or synergimycin) family of antibiotics consist of two components, A and B, that synergistically inhibit protein synthesis by binding to distinct sites on the 50S subunit of the prokaryotic ribosome. The group A components are polyunsaturated macrolactones and the group B components are N₁^α-acylated cyclic hexadepsipeptides (Figure 1). Although the virginiamycins have been used for many years as a growth-promoting additive in livestock feed, limited water




Figure 1. Structures of streptogramin antibiotics. Dihydrovirginiamycin S₁ has a *trans*-hydroxyl group replacing the carbonyl of residue 5.

solubility has hampered the clinical utility of streptogramin antibiotics. Recently, the semisynthetic water-soluble derivatives quinupristin and dalfopristin (marketed as Synercid TM) were approved for the treatment of Gram-positive coccal infections including vancomycin-resistant enterococci (Figure 1).^[1] Here we describe the first solid-phase synthesis of a group B streptogramin. Our synthesis is designed to enable the synthesis of streptogramin B analogues at positions 1', 1, 2, 3, 4, and 6.

The genes responsible for the biosynthesis of pristinamycin I in *Streptomyces pristinaespiralis* and virginiamycin S₁ in

[a] A. Shaginian, M. C. Rosen, Prof. P. J. Belshaw
Department of Chemistry
University of Wisconsin-Madison
Madison, WI 53706 (USA)
Fax: (+1) 608-265-4534
E-mail: belshaw@chem.wisc.edu

[b] B. F. Binkowski, Prof. P. J. Belshaw
Department of Biochemistry
University of Wisconsin-Madison
Madison, WI 53706 (USA)
Fax: (+1) 608-265-4534

Streptomyces virginiae have been sequenced, and the homologous nonribosomal peptide synthetases (NRPS) that assemble these natural products in a template-directed fashion have been identified.^[2] Recent work has shown that it is possible to re-engineer the substrate specificity of NRPSs, thus enabling the possibility of cost-effective production of analogues through engineered biosynthesis in microorganisms.^[3] Although significant progress has been made in the combined chemo-enzymatic synthesis of libraries,^[4] the exclusive biosynthetic production of nonribosomal peptide libraries remains a challenge.

We have developed a solid-phase synthesis of dihydrovirginiamycin S₁ (dhVS₁)^[5] to enable the synthesis of streptogramin B analogues for investigation of structure–activity relationships in these antibiotics. The hexapeptide macrocycle of the streptogramin B antibiotics has many features that make it a favorable scaffold for the identification of analogues with new biological activities: the parent compounds are cell permeable; the macrocycle is rigidified by a *trans*-annular hydrogen bond between the carbonyl oxygen atom of Pro and the amide N–H group of Phg; the conformation of the macrocycle directs the side chains (potential diversity elements) in a radial manner and could provide a diverse set of three-dimensional structures,^[6] and the side chains are projected over a relatively large surface area, a property that may be beneficial for binding to protein–protein interaction surfaces. Protein–protein interactions are of great interest as new pharmacological targets, yet difficult to modulate with small molecules.^[7]

Previous syntheses of streptogramin B natural products^[8] and analogues^[9] have been conducted in solution with closure of the macrocycle through formation of an amide bond from a linear depsipeptide precursor. Along with these total syntheses, efforts toward the production of semi/hemisynthetic analogues revealed several challenges:^[10] compounds containing homochiral *N*-alkyl amino acid triads are sensitive to strong acids, the Phg ester is sensitive to both epimerization and elimination, cyclization is nearly always accompanied by epimerization, and the *des-N*-hydroxypicolinic acid derivatives are susceptible to rearrangements giving inactive macrolactam and oxazoline byproducts.

We targeted the synthesis of dhVS₁, since this analogue is known to be active, the hydroxyl group on the hydroxypipicolinic acid residue provides a handle for attachment to the resin, and this residue has been extensively modified with many analogues retaining activity.^[10c] Our retrosynthesis (Figure 2) disconnects the macrocycle into three subfragments: a linear tetrapeptide anchored to the resin through the hydroxypipicolinic acid, a fragment containing Phg with an ester bond to the side chain of Thr, and the exocyclic 3-hydroxypicolinic acid. These disconnections were chosen to allow cyclization at the Thr1-*D*-Abu2 peptide bond by means of activation of a carbamate-protected Thr to prevent





Figure 2. Retrosynthetic disconnections for dhVS₁. All = allyl, Alloc = allyloxycarbonyl, Boc = *tert*-butyloxycarbonyl.

epimerization during cyclization. This strategy also allows the Phg ester to be constructed in solution and introduced late in the synthesis to minimize complications with this sensitive functionality.

Results and Discussion

The synthesis of Fmoc-*trans*-4-hydroxypipicolinic acid *tert*-butyl ester **3** is outlined in Scheme 1. The commercially available benzylamine salt of Boc-*trans*-4-hydroxypipicolinic acid was silylated and converted to the *tert*-butyl ester (**1**).




Scheme 1. Synthesis of Fmoc-hyPip-OTBu. Reagents and conditions: a) 0.5 M HCl_(aq) in NaCl_(sat), EtOAc, 0 °C, 20 min; b) TBS-Cl, imidazole, 2,6-lutidine, THF, 48 h, 98% for two steps; c) *t*BuOH, DIC, DMAP_(cat), CH₂Cl₂, 94%; d) TMS-OTf (1 equiv), CH₂Cl₂/toluene, 4 h; e) Fmoc-Cl, pyridine, CH₂Cl₂, 15 h, 77% for two steps; f) HF/pyridine, THF, 2 h, 96%. hyPip = (2*S*,4*S*)-4-hydroxypiperidine-2-carboxylic acid, Bn = benzyl, *t*Bu = *tert*-butyl, TBS = *tert*-butyldimethylsilyl, Fmoc = 9-fluorenylmethyloxycarbonyl, THF = tetrahydrofuran, DIC = 1,3-diisopropylcarbodiimide, DMAP = 4-(dimethylamino)pyridine, TMS = trimethylsilyl, Tf = trifluoromethanesulfonyl.


Selective Boc cleavage with one equivalent of TMS-OTf^[11] followed by Fmoc protection afforded **2**. Selective removal of the TBS group in the presence of the *tert*-butyl ester with HF/pyridine afforded **3**.^[12]

The synthesis of the dipeptide amine **5** is shown in Scheme 2. Boc-Thr-OAll^[13] was condensed with Troc-Phg-OH^[14] at –25 °C in the presence of 1,3-diisopropylcarbodiimide (DIC) and a catalytic amount of DMAP to afford ester **4** without epimerization. Troc deprotection with zinc in acetic acid afforded amine **5**.

Our synthesis of dhVS₁ is outlined in Scheme 3. We chose Danishefsky's bis(silyl ether) linker^[15] for attachment of *trans*-4-hydroxypipicolinic (hyPip) to the resin as it is stable to mild bases and palladium cleavage conditions, yet readily



Scheme 2. Synthesis of dipeptide ester **5**. a) Troc-Phg-OH, DIC, DMAP_(cat), CH₂Cl₂, 2 h, −25 °C, 95%; b) Zn, AcOH, 2 h, 88%. Troc = 2,2,2-trichloroethoxycarbonyl.




Scheme 3. Solid-phase synthesis of dhVS₁. a) diisopropyldichlorosilane, imidazole, 30 min; b) hydroxymethyl-polystyrene resin, 48 h; c) 30% piperidine, CH₂Cl₂, 30 min; d) Alloc-MePhe-OH, HOAt, DIC, 2,6-lutidine, DMF, 48 h; e) Pd(PPh₃)₄(cat), Bu₃SnH, 5% AcOH, CH₂Cl₂, 3 h; f) Fmoc-Pro-OH, HOAt, DIC, 2,6-lutidine, DMF, 48 h (×3); g) 30% piperidine, CH₂Cl₂, 30 min; h) Alloc-D-Abu-OH, HOAt, DIC, 2,6-lutidine, DMF, 24 h; i) TMS-OTf, 2,6-lutidine, CH₂Cl₂, 5 h; j) MeOH, 20 min; k) **5**, HOAt, DIC, 2,6-lutidine, DMF, 6 h; l) [Pd(PPh₃)₄]_(cat), PhSiH₃, CH₂Cl₂, 5 h; m) PyAOP, 2,6-lutidine, CH₂Cl₂, 48 h; n) TMS-OTf, 2,6-lutidine, CH₂Cl₂, 2 h, 23 °C, then 20 min, 4 °C; o) 3-hydroxypicolinic acid, PyAOP, 2,6-lutidine, THF, 4 h, 4 °C, then 10 h, 23 °C; p) HF/pyridine, THF, 1 h, 15% overall. HOAt = 1-hydroxy-7-azabenzotriazole, DMF = *N,N*-dimethylformamide, Abu = 2-aminobutyric acid, PyAOP = 7-aza-benzotriazole-1-yloxytris(pyrrolidinophosphonium) hexafluorophosphate.

removed with HF/pyridine. The synthesis commences with loading of Fmoc-hyPip-OtBu (**3**) onto the hydroxymethyl polystyrene resin. Fmoc removal followed by DIC/1-hydroxy-7-azabenzotriazole (HOAt)/2,6-lutidine-mediated coupling^[16] of Alloc-MePhe-OH resulted in the formation of

resin-bound intermediate **6**. Removal of the Alloc protecting group with palladium under mild acidic conditions, and subsequent coupling with Fmoc-Pro-OH using DIC/HOAt/2,6-lutidine yielded the tripeptide resin. Fmoc deprotection and coupling to Alloc-D-Abu-OH yielded resin-bound tetrapeptide **7**. Subsequently, the *tert*-butyl ester was deprotected under neutral conditions (TMS-OTf/lutidine),^[17] and then coupled with amine **5** to yield linear hexapeptide resin **8**. Simultaneous deprotection of the allyl and Alloc groups with palladium, followed by PyAOP-mediated cyclization afforded the Boc-protected macrocycle **9**. Boc removal was accomplished under neutral conditions with TMS-OTf/lutidine, and PyAOP/lutidine-mediated coupling with 3-hydroxypicolinic acid afforded **10**. HF/pyridine-mediated cleavage from resin yielded dhVS₁ in 15% overall isolated yield after purification by silica gel chromatography. LC/MS analyses of synthetic intermediates cleaved from the resin indicated that the on-resin cyclization largely determined the final yield of dhVS₁.

Several issues encountered during the solid-phase synthesis of dhVS₁ are worth noting. In our initial experiments we attempted to employ the allyl ester of hyPip in place of *tert*-butyl ester **3**. However, upon deprotection of Fmoc-MePhe-hyPip(O-resin)-OAll with piperidine, the free amine rapidly cyclized to form the 2,5-diketopiperazine (DKP). The combination of the bulky *tert*-butyl ester on pipecolic acid, Alloc deprotection under acidic conditions, and DIC/HOAt/lutidine coupling under neutral conditions were required to allow successful peptide extension without any DKP formation.


We also investigated approaches to dhVS₁ involving cyclization with 3-hydroxypicolinic acid installed on the exocyclic amine of Thr1. However, solution-phase experiments with model compound **11** revealed a rapid elimination immediately upon activation of Thr, resulting in the cleavage of the ester bond (Scheme 4). This possibly occurs via formation of



Scheme 4. Elimination of N^α-protected Phg during activation of side-chain acylated Thr.

a 5(4*H*)-oxazolone **12** that eliminates to give the unstable intermediate **13**, which was trapped with 4-methoxybenzyl amine to yield **14** (data not shown). Protection of the Thr exocyclic amine as a urethane during cyclization avoided this elimination pathway.

Another potential complication was the instability of 1-(*des*-3-hydroxypicolinoyl) pristinamycin I_A (**15**), as reported by Barriere and co-workers,^[10c] which can rearrange to lactam **16** and oxazoline **17** (Scheme 5). Expecting that basic conditions would promote these rearrangements in the relat-



Scheme 5. Rearrangements of 1-(*des*-3-hydroxypicolinoyl) pristinamycin I_A.

ed compound in our synthesis, we chose to protect this amine with a Boc group (intermediate **9**, Scheme 3), as it can be cleaved under neutral conditions with TMS-OTf/lutidine.^[17] Moreover, in our initial studies we noticed that TMS-OTf could promote epimerization of the sensitive Phg residue. To minimize competing epimerization, O→N acyl shift, and oxazoline formation, the Boc deprotection was carried out in CH₂Cl₂ for 2 h at room temperature. Shorter reaction times at room temperature and longer reaction times (5–6 h) at 4 °C resulted in incomplete deprotection or epimerization of Phg, respectively. Acylation with 3-hydroxypicolinic acid was then achieved in THF with PyAOP/lutidine. Other solvents such as CH₂Cl₂ and DMF and coupling agents such as DIC/HOAt gave less satisfactory results. This strategy of utilizing neutral deprotection and coupling conditions with HOAt-active esters minimizes exposure of the free amine and may prove generally useful for difficult amide bond formations in which undesired side reactions of the free amine compete. These strategies enabled successful acylation of MePhe4 and the exocyclic amine of Thr1, thereby allowing both of these positions to be sites for diversification in our synthetic route.

The conditions for cleavage from resin were also critical to avoid acidic endopeptolysis of the Pro3-MePhe4-hyPip5 triad of *N*-alkyl amino acids.^[10b] Cleavage with HF/pyridine in dichloromethane led exclusively to endopeptolysis from rupture of the MePhe4-hyPip5 peptide bond. Interestingly, the endopeptolysis was solvent-dependent and is completely

avoided in THF or can be suppressed with an excess of pyridine.

To confirm the identity of our synthetic dhVS₁, we prepared semisynthetic dhVS₁ from the natural product virginiamycin S₁ isolated from Stafac,^[18] by reduction with sodium borohydride.^[5] Synthetic dhVS₁ displayed identical ¹H NMR spectral data to the compound prepared from the natural product. To confirm the biological activity of dhVS₁, we assayed our synthetic and semi-synthetic dhVS₁ for activity against *B. subtilis*, both alone and in combination with virginiamycin M (Table 1). Both samples displayed equal activ-

Table 1. Growth inhibition assays. The growth of *B. subtilis* strain BR151 (ATCC 33677) in liquid culture was monitored in the presence of varying concentrations of compound(s).

Compound(s) ^[a]	MIC ^[b] [μg mL ⁻¹]
synthetic dhVS ₁	50
natural dhVS ₁	50
VS ₁	2
VM	3
synthetic dhVS ₁ /VM	1/1.5
natural dhVS ₁ /VM	1/1.5
VS ₁ /VM	0.4/0.6

[a] VS₁/VM compound mixtures were present in a 3:7 molar ratio. dhVS₁ = dihydrovirginiamycin S₁, VS₁ = virginiamycin S₁, VM = virginiamycin M. [b] MIC = minimal concentration required to completely inhibit growth after a 10 h incubation from a starting inoculum of ~2000 cfu mL⁻¹.

ity and a synergistic increase in activity with virginiamycin M, albeit with a slight decrease in potency compared to the parent natural product, consistent with previous reports.^[5]

Conclusion

We have developed a rapid and efficient solid-phase synthesis of dihydrovirginiamycin S₁ that should enable the preparation of novel streptogramin B analogues. These compounds could be used to identify structure–activity relationships in this important class of antibiotics, possibly identifying new compounds with increased potency, the ability to bypass resistance mechanisms,^[19] or completely new biological activities. Having determined conditions for the successful acylation of MePhe4 and the exocyclic amine of Thr1 in solid-phase synthesis, our synthetic route should allow the facile construction of analogues at positions 1', 2, 3, and 4, and variations at Thr1 and Phg6, which could be readily accomplished through the incorporation of appropriate ester-containing fragments.

Experimental Section

General procedures: 1-Hydroxy-7-azabenzotriazole (HOAt) and (7-azabenzotriazole-1-ylxy)tripyrrolidinophosphonium hexafluorophosphate (PyAOP) were obtained from Applied Biosystems, (Foster City, CA). Amino acids were obtained from Advanced ChemTech (Louisville, KY)

and EMD Biosciences (San Diego, CA). Diisopropylchlorosilane was obtained from Fluka (Milwaukee, WI). The benzylamine salt of (2*S*,4*S*)-*N*-Boc-4-hydroxypiperidine-2-carboxylic acid was obtained from Chiro-tech Technology Ltd (Cambridge, UK). Hydroxymethyl polystyrene resin SS, 100–200 mesh, 1% DVB, 1.0 mmol g⁻¹ was obtained from Advanced ChemTech (Louisville, KY). All other reagents were obtained from Aldrich Chemical (Milwaukee, WI) and used without further purification. Solid-phase reactions were conducted inside 50 mL round-bottomed flasks or 10 mL polypropylene poly-prep chromatography columns obtained from Bio-Rad Laboratories (Hercules, CA) and agitated on a Labquake shaker. Tetrahydrofuran (THF) and toluene were distilled from sodium benzophenone ketyl; dichloromethane (CH₂Cl₂) was distilled from phosphorous pentoxide. Analytical thin-layer chromatography (TLC) was carried out on EM Science TLC plates precoated with silica gel 60 F₂₅₄ (250 µm layer thickness). TLC visualization was accomplished by using a UV lamp and/or charring solutions of either ninhydrin or phosphomolybdic acid (PMA). Flash column chromatography (FCC) was performed on Silicycle silica gel 60 (230–400 mesh). ¹H NMR spectra were recorded in deuterated solvents on a Bruker AC-250 (250 MHz), Bruker AC-300 (300 MHz) or a Varian UNITY-500 (500 MHz) spectrometer. Chemical shifts are reported in parts per million (ppm, δ) relative to tetramethylsilane (TMS, δ 0.00) or relative to residual solvent signals (CDCl₃ 7.27 (1) or CD₃CN 1.94 (5)). Coupling constants (*J* values) are given in Hz, and peak multiplicities are denoted by s (singlet), d (doublet), dd (doublet of doublets), ddd (doublet of doublet of doublets), dq (doublet of quartets), dt (doublet of triplets), m (multiplet), q (quartet), and t (triplet). ¹³C NMR spectra were recorded in deuterated solvents on a Bruker AC-250 (62.5 MHz), Bruker AC-300 (75 MHz) or a Varian UNITY-500 (125 MHz) spectrometer. Chemical shifts are reported in parts per million (ppm, δ) relative to residual solvent signals (CDCl₃ 77.23 (3) or CD₃CN 1.39 (7)). For compounds with multiple rotamers all observed signals are reported. Optical rotations were obtained on a Perkin-Elmer 241 digital polarimeter at room temperature with a Na lamp. Concentrations (*c*) are reported in g per 100 mL. Fourier transform infrared (FT-IR) spectra were obtained on a Mattson Polaris instrument. High-resolution electrospray ionization mass spectra (HRESI-MS) were obtained on a Micromass LCT.

Boc-(2*S*,4*S*)-hyPip(OTBS)-OH: Aqueous HCl (0.5 M) saturated with sodium chloride (10 mL) was slowly added to the suspension of the benzylamine salt of (2*S*,4*S*)-*N*-Boc-4-hydroxypiperidine-2-carboxylic acid (1.0 g, 2.84 mmol) in EtOAc (10 mL) at 0°C. The mixture was stirred at 0°C for 20 min, diluted with EtOAc, and extracted with saturated aq NaCl. The organic layer was collected, dried (Na₂SO₄), and concentrated, affording acid as a solid. The obtained acid was dissolved in THF (30 mL) and imidazole (1.2 g, 17.04 mmol), 2,6-lutidine (1.3 mL, 11.36 mmol), and TBS-Cl (1.3 g, 8.52 mmol) were added at 0°C. The reaction mixture was stirred at room temperature under an atmosphere of N₂ for 48 h. The mixture was diluted with EtOAc and extracted with aq HCl (0.1 M, ×2). The organic layer was collected and concentrated. The resultant residue was suspended in MeOH (20 mL), stirred for 5 h, after which the mixture was concentrated and purified by chromatography on silica gel (50:50:1 hexanes/Et₂O/AcOH) to give the side-chain TBS-protected acid as a solid (1.0 g, 98%) that was homogeneous by TLC analysis. *R*_f=0.32 (hexanes/Et₂O/HOAc 25:25:1); [α]_D²⁵=−23.3 (*c*=0.18 in CHCl₃); ¹H NMR (300 MHz, CDCl₃, 25°C): δ=0.060 (d, *J*=1.3 Hz, 6H), 0.87 (s, 9H), 1.45 (s, 9H), 1.72 (m, 3H), 2.36 (m, 1H), 2.98 (m, 1H), 3.65 (m, 1H), 4.01 (m, 1H), 4.92 (m, 1H), 11.35 ppm (s, 1H); ¹³C NMR (75 MHz, CDCl₃, 25°C): δ=−4.8, 17.9, 25.7, 28.2, 34.3, 35.4, 39.8, 40.5, 53.6, 54.5, 66.7, 80.6, 155.2, 155.7, 176.4, 176.6 ppm; FT-IR (KBr pellet): $\tilde{\nu}$ =2954, 2856, 1750, 1630, 1439 cm⁻¹; MS (HRESI-MS) calcd for [C₁₇H₃₂NO₃Si]⁺: 358.2050; found: 358.2045.

Boc-(2*S*,4*S*)-hyPip(OTBS)-OrBu 1: Boc-(2*S*,4*S*)-hyPip(OTBS)-OH (0.92 g, 2.56 mmol) was dissolved in CH₂Cl₂ (5 mL) and anhydrous 2-methyl-2-propanol (0.72 mL, 7.68 mmol) was added, followed by DMAP (94 mg, 0.77 mmol). The solution was cooled to 0°C, and DIC (0.80 mL, 5.12 mmol) in CH₂Cl₂ (5 mL) was injected dropwise over 15 min. The reaction mixture was stirred at 0°C under an atmosphere of N₂ for 15 min and then at room temperature for 5 h. The mixture was diluted with Et₂O and extracted with aq HCl (0.1 M, ×2) and H₂O (×1). The organic layer was collected, concentrated, and purified by chromatography on silica gel (9:1 hexanes/Et₂O) to give **1** as a solid (1.0 g, 94%) that was ho-

mogeneous by TLC analysis. *R*_f=0.66 (hexanes/Et₂O 7:3); [α]_D²⁵=−17.2 (*c*=0.087 in CHCl₃); ¹H NMR (300 MHz, CDCl₃, 25°C): δ=0.065 (d, *J*=0.7 Hz, 6H), 0.88 (s, 9H), 1.44 (s, 9H), 1.47 (s, 10H), 1.60 (m, 1H), 1.79 (m, 1H), 2.30 (m, 1H), 2.99 (m, 1H), 3.58 (m, 1H), 3.99 (m, 1H), 4.74 ppm (m, 1H); ¹³C NMR (75 MHz, CDCl₃, 25°C): δ=−4.6, 18.2, 25.9, 28.1, 28.4, 34.5, 34.8, 36.1, 40.2, 40.7, 54.5, 55.6, 67.0, 79.9, 81.4, 155.5, 155.6, 170.6, 170.8 ppm; FT-IR (thin film): $\tilde{\nu}$ =2976, 2930, 2857, 1739, 1704, 1473 cm⁻¹; MS (HRESI-MS) calcd for [C₂₁H₄₁NO₃Si+Na]⁺: 438.2652; found: 438.2656.

Fmoc-(2*S*,4*S*)-hyPip(OTBS)-OrBu 2: Boc-(2*S*,4*S*)-hyPip(OTBS)-OrBu **1** (30 mg, 0.072 mmol) was dissolved in CH₂Cl₂ (0.7 mL) and treated with a solution of TMS-OTf in toluene (0.292 M, 0.25 mL, 0.073 mmol) at room temperature. The reaction mixture was stirred at room temperature under an atmosphere of N₂ for 4 h and was quenched with MeOH (1 mL), concentrated and purified by chromatography on silica gel (50:1 Et₂O/MeOH) to give the α-amino ester as a liquid that was homogeneous by TLC analysis. The product was dissolved in CH₂Cl₂ (2 mL), pyridine (50 µL, 0.62 mmol) was added, and the system was cooled to 0°C. Fmoc-Cl (26 mg, 0.1 mmol) was added and the reaction mixture was stirred at room temperature under an atmosphere of N₂ for 15 h. The mixture was concentrated and purified by chromatography on silica gel (9:1 hexanes/Et₂O) to give **2** as a solid (30 mg, 77%) that was homogeneous by TLC analysis. *R*_f=0.40 (hexanes/Et₂O 7:3); [α]_D²⁵=−11.4 (*c*=0.70 in CHCl₃); ¹H NMR (300 MHz, CDCl₃, 25°C): δ=0.12 (s, 6H), 0.93 (s, 9H), 1.46 (m, 1H), 1.50 (s, 9H), 1.66 (m, 1H), 1.87 (m, 1H), 2.40 (m, 1H), 3.17 (m, 1H), 3.67 (m, 1H), 4.14 (m, 1H), 4.35 (m, 3H), 4.89 (m, 1H), 7.36 (m, 4H), 7.60 (m, 2H), 7.78 ppm (d, *J*=7.5 Hz, 2H); ¹³C NMR (75 MHz, CDCl₃, 25°C): δ=−4.5, 18.3, 26.0, 28.2, 34.7, 34.8, 36.3, 40.6, 40.7, 47.4, 47.5, 55.2, 55.3, 66.9, 68.0, 82.0, 82.2, 120.1, 125.3, 127.3, 127.8, 141.5, 144.1, 144.3, 155.9, 156.3, 170.4 ppm; FT-IR (thin film): $\tilde{\nu}$ =3067, 2953, 2929, 1736, 1708, 1451 cm⁻¹; MS (HRESI-MS) calcd for [C₃₁H₄₃NO₃Si+Na]⁺: 560.2808; found: 560.2815.

Fmoc-(2*S*,4*S*)-hyPip(OTBS)-OrBu 3: Fmoc-(2*S*,4*S*)-hyPip(OTBS)-OrBu **2** (90 mg, 0.167 mmol) was dissolved in THF (5 mL) and HF/pyridine (3.0 mL) was injected at 0°C. The reaction mixture was stirred at room temperature for 2 h and diluted with Et₂O. The mixture was extracted with saturated aq NaHCO₃ (×1), aq HCl (0.1 M, ×2), and H₂O (×1). The organic layer was collected, concentrated, and purified by chromatography on silica gel (1:4 hexanes/Et₂O) to give **3** as a solid (68 mg, 96%) that was homogeneous by TLC analysis. *R*_f=0.45 (Et₂O); [α]_D²⁵=−23.2 (*c*=1.10 in CHCl₃); ¹H NMR (300 MHz, CDCl₃, 25°C): δ=1.26 (m, 1H), 1.47 (s, 9H), 1.60 (m, 1H), 1.97 (m, 1H), 2.08 (s, 1H), 2.50 (m, 1H), 3.14 (m, 1H), 3.70 (m, 1H), 4.12 (m, 1H), 4.36 (m, 3H), 4.90 (m, 1H), 7.35 (m, 4H), 7.58 (m, 2H), 7.78 ppm (d, *J*=7.6 Hz, 2H); ¹³C NMR (75 MHz, CDCl₃, 25°C): δ=28.2, 34.2, 35.7, 40.4, 40.6, 47.4, 47.5, 55.0, 55.1, 66.0, 66.1, 68.0, 82.2, 82.4, 120.2, 125.2, 127.2, 127.9, 141.4, 144.0, 144.2, 155.9, 156.3, 170.2 ppm; FT-IR (thin film): $\tilde{\nu}$ =3435, 3066, 2975, 2931, 1733, 1704, 1451 cm⁻¹; MS (HRESI-MS) calcd for [C₂₅H₂₉NO₃+Na]⁺: 446.1943; found: 446.1921.

Alloc-L-MePhe-OH: A solution of allyl chloroformate (1.5 mL, 13.9 mmol) in dioxane (20 mL) and aq NaOH (1 M, 20 mL) were simultaneously added dropwise at 0°C to a solution of H-L-MePhe-OH·HCl (2.0 g, 9.27 mmol), H₂O (30 mL), aq NaOH (1 M, 20 mL), and Et₂O (20 mL). The ice-bath was removed, and the reaction mixture was stirred for 12 h at room temperature. The mixture was diluted with EtOAc and extracted with saturated aq NaHCO₃. The aqueous layer was collected, acidified with concentrated HCl, and extracted with EtOAc. The organic layer was collected, dried (Na₂SO₄), and concentrated affording a solid (1.95 g, 80%) that was homogeneous by TLC analysis. *R*_f=0.35 (hexanes/Et₂O/HOAc 30:20:1); [α]_D²⁵=−65.4 (*c*=2.09 in MeOH); ¹H NMR (250 MHz, CD₃CN, 67°C): δ=2.81 (s, 3H), 3.10 (dd, *J*=10.7, 14.5 Hz, 1H), 3.33 (dd, *J*=5.2, 14.4 Hz, 1H), 4.51 (d, *J*=5.2 Hz, 2H), 4.88 (dd, *J*=5.2, 10.5 Hz, 1H), 5.20 (m, 2H), 5.89 (m, 1H), 7.28 (m, 5H), 8.24 ppm (s, 1H); ¹³C NMR (62.5 MHz, CD₃CN, 67°C): δ=33.0, 36.1, 61.9, 67.2, 117.8, 127.9, 129.8, 130.3, 134.7, 139.3, 157.5, 172.8 ppm; FT-IR (thin film): $\tilde{\nu}$ =3078, 3029 2938, 1743, 1700, 1653, 1401 cm⁻¹; MS (HRESI-MS) calcd for [C₁₄H₁₆NO₄][−]: 262.1079; found: 262.1069.

Alloc-D-Abu-OH: (D)-Aminobutyric acid (1.0 g, 9.7 mmol) was dissolved in a mixture of H₂O (15 mL), aq NaOH (1 M, 10 mL), and Et₂O (10 mL) and the system cooled to 0°C. A solution of allyl chloroformate (1.4 mL, 12.9 mmol) in dioxane (13 mL) was added slowly and simultaneously

with aq NaOH (1 M, 13 mL). The ice-bath was removed, and the reaction mixture was stirred for 16 h at room temperature. The mixture was diluted with EtOAc and extracted with saturated aq NaHCO₃. The aqueous layer was collected, acidified with concentrated HCl, and extracted with EtOAc. The organic layer was collected, dried (Na₂SO₄), and concentrated, affording a liquid (1.85 g, 100%) that was homogeneous by TLC analysis. R_f = 0.50 (EtOAc/HOAc 50:1); $[\alpha]_D^{25}$ = -10.0 (c = 0.70 in CHCl₃); ¹H NMR (300 MHz, CD₃CN, 25 °C): δ = 0.94 (t, J = 7.4 Hz, 3H), 1.78 (m, 2H), 4.10 (m, 1H), 4.53 (d, J = 5.0 Hz, 2H), 5.18 (dd, J = 1.4, 10.5 Hz, 1H), 5.29 (d, J = 17.3 Hz, 1H), 5.90 (m, 1H), 6.02 (d, J = 7.0 Hz, 1H), 9.61 ppm (s, 1H); ¹³C NMR (75 MHz, CD₃CN, 25 °C): δ = 10.5, 25.7, 56.1, 66.3, 118.3, 134.2, 157.4, 174.9 ppm; FT-IR (thin film): $\tilde{\nu}$ = 3323, 3085, 2973, 2882, 1718, 1533, 1235 cm⁻¹; MS (HRESI-MS) calcd for [C₈H₁₂NO₄]⁻: 186.0764; found: 186.0771.

Ester 4: Boc-L-Thr-OAll (0.95 g, 3.66 mmol) was dissolved in CH₂Cl₂ (15 mL), and Troc-L-Phg-OH (1.32 g, 4.03 mmol) was added. The system was cooled to -30 °C, and DIC (0.63 mL, 4.03 mmol) was injected, followed by DMAP (4.5 mg, 0.0366 mmol). The reaction mixture was maintained between -30 and -20 °C under an atmosphere of N₂ for 2 h, diluted with Et₂O, and quenched with aq HCl (0.1 M). The mixture was extracted with aq HCl (0.1 M, $\times$ 2), saturated aq NaHCO₃ ($\times$ 2), and H₂O ($\times$ 1). The organic layer was collected and concentrated. The crude residue was purified by chromatography on silica gel (2.3:1 hexanes/Et₂O) to give **4** as a solid (1.98 g, 95%) that was homogeneous by TLC analysis. R_f = 0.58 (hexanes/Et₂O 1:1); $[\alpha]_D^{25}$ = +43.9 (c = 0.62 in CHCl₃); ¹H NMR (300 MHz, CDCl₃, 25 °C): δ = 1.16 (d, J = 6.5 Hz, 3H), 1.45 (s, 9H), 4.48 (dd, J = 2.5, 9.5 Hz, 1H), 4.61 (d, J = 6.0 Hz, 2H), 4.68 (d, J = 12.0 Hz, 1H), 4.76 (d, J = 12.2 Hz, 1H), 5.25 (m, 4H), 5.48 (m, 1H), 5.85 (m, 1H), 5.98 (d, J = 7.1 Hz, 1H), 7.36 ppm (m, 5H); ¹³C NMR (75 MHz, CDCl₃, 25 °C): δ = 16.4, 28.4, 57.2, 58.3, 66.7, 72.8, 74.9, 80.6, 95.4, 119.5, 127.3, 129.1, 129.3, 131.5, 135.7, 153.7, 155.9, 169.4, 169.7 ppm; FT-IR (thin film): $\tilde{\nu}$ = 3336, 2980, 1746, 1720, 1508 cm⁻¹; MS (HRESI-MS) calcd for [C₂₃H₂₉Cl₃N₂O₈+Na]⁺: 589.0887; found: 589.0867.

Amine 5: Ester **4** (1.8 g, 3.17 mmol) was dissolved in AcOH (5 mL) and zinc dust (2 g) was added. The reaction mixture was stirred at room temperature for 1 h, after which additional AcOH (1.5 mL) and zinc dust (2 g) were added. The mixture was stirred at room temperature for another hour and purified by chromatography on silica gel (10:1 Et₂O/EtOAc) affording **5** as a solid (1.1 g, 88%) that was homogeneous by TLC analysis. R_f = 0.52 (Et₂O/MeOH 20:1); $[\alpha]_D^{25}$ = +66.7 (c = 0.75 in CHCl₃); ¹H NMR (300 MHz, CD₃CN, 25 °C): δ = 1.11 (d, J = 6.4 Hz, 3H), 1.42 (s, 9H), 1.95 (s, 2H), 4.42 (dd, J = 2.3, 9.5 Hz, 1H), 4.54 (m, 2H), 4.75 (s, 1H), 5.20 (dd, J = 1.1, 10.4 Hz, 1H), 5.30 (ddd, J = 1.5, 3.1, 17.4 Hz, 1H), 5.40 (m, 1H), 5.86 (m, 1H), 5.89 (d, J = 10.5 Hz, 1H), 7.38 ppm (m, 5H); ¹³C NMR (75 MHz, CDCl₃, 25 °C): δ = 17.0, 28.4, 57.1, 58.4, 66.8, 73.1, 80.4, 119.1, 127.3, 129.3, 129.4, 131.8, 136.9, 156.3, 170.9, 171.0 ppm; FT-IR (thin film): $\tilde{\nu}$ = 3313, 2981, 2936, 1745, 1716, 1506 cm⁻¹; MS (HRESI-MS) calcd for [C₂₀H₂₈N₂O₆+Na]⁺: 415.1845; found: 415.1837.

Resin-bound dipeptide 6: Imidazole (0.30 g, 4.43 mmol) was dissolved in CH₂Cl₂ (4.0 mL) and diisopropyldichlorosilane (0.16 mL, 0.89 mmol) was injected dropwise. The mixture was stirred at room temperature under an atmosphere of N₂ for 5 min, and a solution of alcohol **3** (0.375 g, 0.885 mmol) in CH₂Cl₂ (3.0 mL) was added slowly dropwise over 15 min with a canula. The mixture was stirred at room temperature under an atmosphere of N₂ for 30 min, followed by addition of the hydroxymethyl polystyrene resin (0.65 g, 0.65 mmol). The mixture was agitated at room temperature for 48 h, drained, and washed with MeOH (20 mL), CH₂Cl₂ (20 mL), and Et₂O (20 mL). The resin was dried under vacuum and subjected to Fmoc quantitation. The loading level was determined to be 0.50 mmol g⁻¹. The resin was then treated with a solution of 30% piperidine in CH₂Cl₂ (20 mL) for 30 min, drained, and washed with CH₂Cl₂ (20 mL), MeCN (20 mL), and again with CH₂Cl₂ (20 mL). The resin was dried under vacuum and treated with Alloc-L-MePhe-OH (0.70 g, 2.66 mmol), a solution of HOAt in DMF (0.5 M, 10 mL, 5.0 mmol), DIC (0.78 mL, 5.0 mmol), and 2,6-lutidine (1.16 mL, 10.0 mmol). The mixture was agitated for 48 h at room temperature, drained, and washed with CH₂Cl₂ (20 mL), MeOH (20 mL), MeCN (20 mL), and again with CH₂Cl₂ (20 mL). The resin was dried under vacuum.

Resin-bound tetrapeptide 7: The resin-bound dipeptide **6** was suspended in a 5% solution of AcOH in CH₂Cl₂ (10.0 mL) and treated with tributyl-

tin hydride (1.43 mL, 5.31 mmol) and tetrakis(triphenylphosphine)palladium(o) (100 mg, 0.087 mmol). The mixture was agitated at room temperature in the dark for 3 h, drained, and washed with CH₂Cl₂ (20 mL), MeCN (20 mL), and again with CH₂Cl₂ (20 mL). The resin was dried under vacuum and treated with Fmoc-L-Pro-OH (0.90 g, 2.66 mmol), a solution of HOAt in DMF (0.5 M, 10 mL, 5.0 mmol), DIC (0.78 mL, 5.0 mmol), and 2,6-lutidine (1.16 mL, 10.0 mmol). The mixture was agitated for 48 h at room temperature, drained, and washed with CH₂Cl₂ (20 mL), MeOH (20 mL), MeCN (20 mL), and again with CH₂Cl₂ (20 mL). The same coupling protocol was repeated again twice, after which the resin was washed and dried under vacuum. The resin was then treated with a solution of 30% piperidine in CH₂Cl₂ (20 mL) for 30 min, drained, and washed with CH₂Cl₂ (20 mL), MeCN (20 mL), and again with CH₂Cl₂ (20 mL). The resin was dried under vacuum, suspended in CH₂Cl₂ (5.0 mL), and treated with a solution of Alloc-D-Abu-OH in CH₂Cl₂ (0.48 M, 5.5 mL, 2.66 mmol), PyAOP (2.6 g, 5.0 mmol), and 2,6-lutidine (1.16 mL, 10.0 mmol). The mixture was agitated for 24 h at room temperature, drained, and washed with CH₂Cl₂ (20 mL), MeOH (20 mL), MeCN (20 mL), and again with CH₂Cl₂ (20 mL). The resin was dried under vacuum.

Resin-bound linear hexapeptide 8: The resin-bound tetrapeptide **7** was suspended in CH₂Cl₂ (4.5 mL) and treated with 2,6-lutidine (4.0 mL, 34.5 mmol) and TMS-OTf (3.0 mL, 16.6 mmol). The mixture was agitated at room temperature for 5 h, drained, and washed with CH₂Cl₂ (20 mL), MeOH (20 mL), MeCN (20 mL), and again with CH₂Cl₂ (20 mL). The resin was suspended in MeOH (10 mL) and agitated at room temperature for 20 min, after which it was drained and washed with CH₂Cl₂ (20 mL), MeOH (20 mL), MeCN (20 mL), and again with CH₂Cl₂ (20 mL). The resin was dried under vacuum, suspended in a solution of HOAt in DMF (0.5 M, 10 mL, 5.0 mmol), and treated with amine **5** (0.69 g 1.77 mmol), DIC (0.78 mL, 5.0 mmol), and 2,6-lutidine (1.16 mL, 10.0 mmol). The mixture was agitated for 6 h at room temperature, drained, and washed with CH₂Cl₂ (20 mL), MeOH (20 mL), MeCN (20 mL), and again with CH₂Cl₂ (20 mL). The resin was dried under vacuum.

Resin-bound cyclic hexapeptide 9: The resin-bound linear hexapeptide **8** (690 mg, 0.226 mmol, based on 0.5 mmol g⁻¹ initial loading and subsequent weight increase of the resin) was placed into a 10 mL polypropylene poly-prep chromatography column. The resin was suspended in CH₂Cl₂ (6.0 mL), treated with phenylsilane (2.0 mL, 16.2 mmol), H₂O (100 μ L), and tetrakis(triphenylphosphine)palladium(o) (100 mg, 0.087 mmol). The mixture was agitated at room temperature in the dark for 5 h, drained, and washed with CH₂Cl₂ (20 mL), MeOH (20 mL), MeCN (20 mL), and again with CH₂Cl₂ (20 mL). The resin was dried under vacuum, resuspended in CH₂Cl₂ (8.0 mL), and treated with PyAOP (0.50 g, 0.96 mmol), and 2,6-lutidine (1.0 mL, 8.61 mmol). The mixture was agitated for 48 h at room temperature, drained, and washed with CH₂Cl₂ (20 mL), MeOH (20 mL), MeCN (20 mL), and again with CH₂Cl₂ (20 mL). The resin was dried under vacuum. All the subsequent reactions through the completion of the synthesis were conducted in the same poly-prep chromatography column.

Resin-bound acylated macrocycle 10: The resin-bound cyclic hexapeptide **9** was suspended in CH₂Cl₂ (4.0 mL) and treated with 2,6-lutidine (3.0 mL, 25.8 mmol) and TMS-OTf (2.0 mL, 11.1 mmol). The mixture was agitated at room temperature for 2 h and then for 25 min at 4 °C. The resin was washed with precooled-to-4 °C THF (20 mL), immediately suspended in precooled-to-4 °C THF (6.0 mL), and treated with 3-hydroxypicolinic acid (0.20 g, 1.44 mmol), PyAOP (0.50 g, 0.96 mmol), and 2,6-lutidine (0.60 mL, 5.17 mmol). The mixture was agitated at 4 °C for 4 h and then for 10 h at room temperature. The resin was drained and washed with CH₂Cl₂ (20 mL), MeOH (20 mL), THF (20 mL), DMF (20 mL), MeCN (20 mL), and again with CH₂Cl₂ (20 mL). The resin was dried under vacuum.

Dihydrovirginiamycin S₁: The resin-bound macrocycle **10** was suspended in THF (7.0 mL) and treated with HF/pyridine (1.0 mL). The resin was agitated at room temperature for 1 h. The resin was drained and washed with THF (20 mL), methoxytrimethylsilane (20.0 mL, 145.64 mmol), CH₂Cl₂ (20 mL), MeOH (20 mL), MeCN (20 mL), and again with CH₂Cl₂ (20 mL). All the washes were combined with the original filtrate, stirred at room temperature for 1 h and, concentrated. The residual amount of pyridine was removed under vacuum. The product was puri-

fied by chromatography on silica gel (25:1 CH₂Cl₂/MeOH) to give dihydrovirginiamycin S₁ (28 mg, 15%) as a solid that was homogeneous by TLC analysis. R_f =0.32 (CH₂Cl₂/MeOH 20:1); $[\alpha]_D^{25}=-4.4$ ($c=0.54$ in CHCl₃); ¹H NMR (500 MHz, CDCl₃, 25 °C): δ =0.33 (dt, $J=11.6, 5.1$ Hz, 1H; 5 β_2), 0.92 (t, $J=7.3$ Hz, 3H; 2 γ), 1.25 (m, 1H; 5 δ_2), 1.14 (m, 1H; 3 β_1), 1.33 (d, $J=6.5$ Hz, 3H; 1 γ), 1.31 (m, 1H; 3 γ_2), 1.33 (d, $J=6.5$ Hz, 3H; 1 γ), 1.58 (m, 1H; 3 γ_1), 1.67 (m, 1H; 2 β_2), 1.73 (m, 1H; 2 β_1), 1.90 (m, 1H; 5 δ_1), 1.97 (m, 1H; 3 β_2), 2.38 (dd, $J=12.3, 4.8$ Hz, 1H; 5 β_1), 2.45 (dt, $J=13.4, 2.1$ Hz, 1H; 5 ϵ_2), 3.11 (s, 3H; 4N-Me), 3.13 (m, 1H; 4 β_2), 3.25 (dd, $J=14.6, 8.6$ Hz, 1H; 4 β_1), 3.33 (q, $J=7.5$ Hz, 1H; 3 δ_2), 3.51 (m, 1H; 3 δ_1), 4.27 (m, 1H; 5 γ), 4.51 (t, $J=6.7$ Hz, 1H; 3 α), 4.60 (d, $J=13.7$ Hz, 1H; 5 ϵ_1), 4.78 (q, $J=7.4$ Hz, 1H; 2 α), 4.85 (dd, $J=9.6, 1.2$ Hz, 1H; 1 α), 5.12 (m, 1H; 5 α), 5.43 (t, $J=8.1$ Hz, 1H; 4 α), 5.61 (d, $J=7.8$ Hz, 1H; 6 α), 5.89 (dq, $J=6.7, 1.2$ Hz, 1H; 1 β), 6.60 (d, $J=9.3$ Hz, 1H; 2NH), 7.10 (m, 2H; aromatic), 7.17 (dd, $J=8.5, 4.3$ Hz, 1H; 1' H_3), 7.29 (m, 9H; aromatic), 7.70 (dd, $J=4.4, 1.1$ Hz, 1H; 1' H_6), 8.38 (d, $J=9.5$ Hz, 1H; 1'NH), 8.58 (d, $J=7.9$ Hz, 1H; 6NH), 11.67 ppm (s, 1H; 1'OH); ¹³C NMR (125 MHz, CDCl₃, 25 °C): δ =10.3, 16.7, 25.0, 25.3, 27.9, 31.0, 34.0, 35.5, 35.6, 38.1, 47.9, 51.8, 52.1, 56.3, 56.9, 57.7, 57.8, 65.0, 71.5, 127.0, 127.6, 128.2, 128.4, 129.0, 129.1, 129.3, 130.5, 135.7, 136.2, 139.9, 158.6, 167.6, 168.8, 169.7, 170.3, 170.5, 171.4, 173.0 ppm; FT-IR (thin film): $\tilde{\nu}$ =3344, 3272, 2958, 2917, 2851, 1739, 1675, 1628, 1517, 1448 cm⁻¹; MS (HRESI-MS) calcd for [C₄₃H₅₁N₇O₁₀+Na]⁺: 848.3595; found: 848.3575.

Acknowledgements

We thank Prof. B. Weisblum for advice and bacterial strains and R. C. Nelson for assistance with spectral characterization. We gratefully acknowledge the NIH (GM065406), the W. M. Keck Foundation and the Burroughs Wellcome Fund for financial support of this work, and NSF (CHE-9208463) and NIH (RR08389) for support of NMR facilities.

- [1] J. C. Barriere, N. Berthaud, D. Beyer, S. Dutka-Malen, J. M. Paris, J. F. Desnottes, *Curr. Pharm. Des.* **1998**, *4*, 155.
- [2] a) D. Thibaut, D. Bisch, N. Ratet, L. Maton, M. Couder, L. Debussche, F. Blanche, *J. Bacteriol.* **1997**, *179*, 697; b) V. Blanc, P. Gil, N. Bamas-Jacques, S. Lorenzon, M. Zagorec, J. Schleuniger, D. Bisch, F. Blanche, L. Debussche, J. Crouzet, D. Thibaut, *Mol. Microbiol.* **1997**, *23*, 191; c) V. De Crecy-Lagard, W. Saurin, D. Thibaut, P. Gil, L. Naudin, J. Crouzet, V. Blanc, *Antimicrob. Agents Chemother.* **1997**, *41*, 1904; d) W. Namwat, Y. Kamioka, H. Kinoshita, Y. Yamada, T. Nihira, *Gene* **2002**, *286*, 283.

- [3] a) P. J. Belshaw, C. T. Walsh, T. Stachelhaus, *Science* **1999**, *284*, 486; b) K. Eppelmann, T. Stachelhaus, M. A. Marahiel, *Biochemistry* **2002**, *41*, 9718.
- [4] R. M. Kohli, C. T. Walsh, M. D. Burkart, *Nature* **2002**, *418*, 658.
- [5] G. Janssen, J. Anne, H. Vanderhaeghe, *J. Antibiot.* **1977**, *30*, 141.
- [6] a) M. J. O. Anteunis, R. E. A. Callens, D. K. Tavernier, *Eur. J. Biochem.* **1975**, *58*, 259; b) J. P. Declercq, G. Germain, M. Van Meerssche, S. E. Hull, M. J. Irwin, *Acta Crystallogr. Sect. B* **1978**, *34*, 3644.
- [7] P. L. Toogood, *J. Med. Chem.* **2002**, *45*, 1543.
- [8] H. Kessler, M. Kuehn, T. Loeschner, *Liebigs Ann. Chem.* **1986**, 21.
- [9] a) M. A. Ondetti, P. L. Thomas, *J. Am. Chem. Soc.* **1965**, *87*, 4373; b) G. Jolles, J. Bouchaudon, *Peptides, Proc. Eur. Pept. Symp.* (Eds.: H. C. Beyerman, A. Van de Linde, W. Massen van der Brink), North Holland, Amsterdam, **1967**, p. 258; c) H. Kessler, B. Kutscher, G. Mager, E. Grell, *Liebigs Ann. Chem.* **1983**, 1541; d) H. Kessler, M. Kuehn, T. Loeschner, *Liebigs Ann. Chem.* **1986**, 1; e) M. J. O. Anteunis, C. Van der Auwera, L. Vanfleteren, F. Borremans, *Bull. Soc. Chim. Belg.* **1988**, *97*, 135; f) M. C. Moerman, M. J. O. Anteunis, *Int. J. Pept. Protein Res.* **1993**, *41*, 102; g) J. L. Robinson, R. E. Taylor, L. A. Liotta, M. L. Bolla, E. V. Azevedo, I. Medina, S. R. McAlpine, *Tetrahedron Lett.* **2004**, *45*, 2147.
- [10] a) M. J. O. Anteunis, N. K. Sharma, *Bull. Soc. Chim. Belg.* **1988**, *97*, 281; b) M. J. O. Anteunis, C. Van der Auwera, *Int. J. Pept. Protein Res.* **1988**, *31*, 301; c) J. M. Paris, J. C. Barriere, C. Smith, P. E. Bost, *Recent Prog. Chem. Synth. Antibiot.* **1990**, 183; d) M. C. Moerman, M. J. O. Anteunis, *Bull. Soc. Chim. Belg.* **1991**, *100*, 647; e) J.-C. Barriere, E. Bacque, G. Puchault, Y. Quenet, C. Molherat, J. Cassayre, J.-M. Paris, *Tetrahedron* **1998**, *54*, 12859.
- [11] D. Y. Maeda, J. E. Ishmael, T. F. Murray, J. V. Aldrich, *J. Med. Chem.* **2000**, *43*, 3941.
- [12] U. Schmidt, F. Stabler, A. Lieberknecht, *Synthesis* **1992**, 482.
- [13] N. Bayo, J. C. Jimenez, L. Rivas, E. Nicolas, F. Albericio, *Chem. Eur. J.* **2003**, *9*, 1096.
- [14] H. Eckert, I. Ugi, *Liebigs Ann. Chem.* **1979**, 278.
- [15] K. A. Savin, J. C. G. Woo, S. J. Danishefsky, *J. Org. Chem.* **1999**, *64*, 4183.
- [16] L. A. Carpino, *J. Am. Chem. Soc.* **1993**, *115*, 4397.
- [17] A. J. Zhang, D. H. Russell, J. Zhu, K. Burgess, *Tetrahedron Lett.* **1998**, *39*, 7439.
- [18] N. K. Sharma, M. J. O. Anteunis, *Bull. Soc. Chim. Belg.* **1988**, *97*, 193.
- [19] N. J. Johnston, T. A. Mukhtar, G. D. Wright, *Curr. Drug Targets* **2002**, *3*, 335.

Received: March 19, 2004
Published online: July 19, 2004